72 hours. From symptom onset. The antiviral treatment window for covid. There’s a study, overlooked by almost everyone, that shows this.

Title: “Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate” Abstract: “A total of 1265 COVID-19 patients with an average age of 44.5 years were studied…41% with at least one comorbidity…No patient treated within the first 72 h of illness died.” [not a small study and included about 500Continue reading “72 hours. From symptom onset. The antiviral treatment window for covid. There’s a study, overlooked by almost everyone, that shows this.”

The FDA’s Big Fat Hydroxychloroquine Blunder

The blunder is in this comment from the FDA’s revocation of its EUA for hydroxychloroquine: Hospitalized patients were likely to have greater prospect of benefit (compared to ambulatory patients with mild illness) and could be more closely monitored for potential toxicity, although it was recognized that enrollment in a clinical trial would be the bestContinue reading “The FDA’s Big Fat Hydroxychloroquine Blunder”